Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
55 hedge funds and large institutions have $13.3M invested in Navidea Biopharmaceuticals Inc. in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 15 reducing their positions, and 14 closing their positions.
24% more capital invested
Capital invested by funds: $10.7M → $13.3M (+$2.55M)
13% less funds holding
Funds holding: 63 → 55 (-8)
53% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 15
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
91% less call options, than puts
Call options by funds: $10K | Put options by funds: $116K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$924K |
| 2 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$190K |
| 3 |
SIM
Spark Investment Management
New York
|
+$149K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$34.7K |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$31.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$2.06M |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$297K |
| 3 |
Millennium Management
New York
|
-$234K |
| 4 |
LCM
Laurion Capital Management
New York
|
-$233K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$217K |
NAVB Hedge Fund Activity: Q3 2016 in Review
55 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2016, worth a combined $13.3M — up 24% from $10.7M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of NAVB and 6 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 7 added.
The largest buyer was BlackRock Institutional Trust, adding an estimated $924K. The largest seller was Goldman Sachs, cutting an estimated $2.06M.
- 55 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2016, down from 63 in Q2 2016.
- Funds reported $13.3M of Navidea Biopharmaceuticals Inc. stock for Q3 2016, up 24% quarter-over-quarter.
- 6 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2016 and 14 closed out, a net change of -8 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2016 was BlackRock Institutional Trust, an estimated $924K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q3 2016 was Goldman Sachs, an estimated $2.06M sold.
Based on aggregated 13F filings for Q3 2016.